Board of Directors

show all

David F. Hale
Director and Chairman of the Board: David F. Hale has been Chairman since February 2004 and has served as a member of our board of directors since June 2000. Mr. Hale currently serves as Chairman and Chief Executive Officer of Hale BioPharma Ventures, LLC. and as Executive Chairman of Biocept, Inc. Mr. Hale has served as the Chairman of the board of directors at Somaxon since its founding in August 2003. Previously Mr. Hale was President and Chief Executive Officer of CancerVax Corporation and also served as a director. Mr. Hale was previously Chairman of Micromet, Inc. (a successor company to CancerVax) until Micromet was acquired by Amgen Inc. Prior to joining CancerVax, Mr. Hale served as President and Chief Executive Officer and a director of Women First HealthCare, Inc. He previously served as Chairman, President and Chief Executive Officer of Gensia Inc., which became Gensia Sicor Inc. Mr. Prior to joining Gensia, Mr. Hale served as Chief Operating Officer, President, Chief Executive Officer and a director of Hybritech, Incorporated. Mr. Hale holds a B.A. in biology and chemistry from Jacksonville State University.

Member of the Audit Committee
Member of the Compensation Committee
Gerald T. Proehl
Director, President and Chief Executive Officer: Gerald T. Proehl serves as our President and Chief Executive Officer and as a director. Mr. Proehl has served in these capacities since January 2002 and previously served as President and Chief Operating Officer. Mr. Proehl joined Santarus in 1999 as Vice President, Marketing and Business Development. Prior to joining Santarus, Mr. Proehl was with Hoechst Marion Roussel, Inc., a global pharmaceutical company, for 14 years, where he served in various capacities, including Vice President of Global Marketing, and held responsibilities in multiple therapeutic areas including gastrointestinal, cardiovascular, wound care and central nervous system. While at Hoechst Marion Roussel, Mr. Proehl was responsible for the marketing of gastrointestinal products Carafate® and Pentasa®, among products in several other therapeutic areas. Mr. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst College.
Daniel D. Burgess
Director: Daniel D. Burgess has served as a member of our board of directors since July 2004. Since June 2011, Mr. Burgess has been President and Chief Executive Officer of Rempex Pharmaceuticals, Inc., a private biopharmaceutical company. From May 2007 Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma Inc. in 2011. Previously, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Harbor BioSciences, Inc., formerly Hollis-Eden Pharmaceuticals, Inc. Prior to Hollis-Eden, Mr. Burgess spent ten years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited) where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.

Chair of the Audit Committee
Michael G. Carter
Director: Michael G. Carter, M.B., Ch.B., F.R.C.P. (U.K.) has served as a member of our board of directors since February 2005. Dr. Carter has been a venture partner at S.V. Life Sciences Advisers LLP since 1998. He is retired from Zeneca, PLC, a publicly traded global pharmaceutical company. During his 12 years at Zeneca, Dr. Carter served as International Medical Director and International Marketing Director. Prior to joining Zeneca, Dr. Carter held several positions with Roche Products, Ltd. Dr. Carter currently serves as a director of GTx, Inc., a men's health biotechnology company, in the U.S. He is a member of the Strategic Advisory Board of Cowen Healthcare Royalty Fund. He is also an elected fellow of the Royal Pharmaceutical Society, Faculty of Pharmaceutical Medicine, and of the Royal College of Physicians of Edinburgh. Dr. Carter holds a bachelor's degree in pharmacy from London University (U.K.) and a medical degree from Sheffield University Medical School (U.K.).

Member of the Nominating and Corporate Governance Committee
Alessandro E. Della Chà
Director: Alessandro E. Della Chà has served as a member of our board of directors since April 2012. Since 1997, Mr. Della Chà has been a senior partner of Studio Legale Edoardo Ricci e Associati, a leading boutique commercial law firm in Milan, Italy and has served as a co-managing director of the firm since 2003. Mr. Della Chà has represented Italian companies and banks in litigation, commercial and bankruptcy matters, with significant experience in the fields of capital market transactions, IPOs, private placements, corporate governance issues and corporate restructurings. He currently serves as a director of Cosmo Pharmaceuticals S.p.A. Mr. Della Chà holds a degree in law from the Università degli Studi di Milano and a Masters in European Commercial Law from the University of Leicester, England.
Michael E. Herman
Director: Michael E. Herman has served as a member of our board of directors since September 2003. Mr. Herman has previously served as President of the Kansas City Royals Baseball Club. He also served as Chairman of the Finance and Investment Committee of the Kauffman Foundation, and was its President for five years. Mr. Herman served 16 years as the Executive Vice President and Chief Financial Officer of Marion Laboratories. Mr. Herman is a director of Senomyx, Inc. and also is a Trustee of Rensselaer Polytechnic Institute and the University of Chicago Graduate School of Business. Mr. Herman holds a B.S. in metallurgical engineering from Rensselaer Polytechnic Institute and an M.B.A. from the University of Chicago.

Member of the Nominating and Corporate Governance Committee
Chair of the Compensation Committee
Ted W. Love M.D.
Director: Ted W. Love, M.D. has served as a member of our board of directors since March 2005. Since February 2010, he has served as Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals, Inc., and in January 2011 he assumed responsibility for technical operations. He previously served for more than seven years as President and Chief Executive Officer of Nuvelo, Inc. having joined the company in January 2001 as President and Chief Operating Officer. He also served as a director of Nuvelo and Chairman of the board of directors. He joined Nuvelo from Theravance, Inc. where he served as Senior Vice President of Development and prior to that, he spent six years at Genentech, Inc. holding a number of senior management positions in medical affairs and product development. Dr. Love currently serves on the board of directors of Affymax, Inc., Bio-Rad Laboratories, Inc. and the California Institute for Regenerative Medicine (CIRM) Independent Citizen's Oversight Committee. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.

Chair of the Nominating and Corporate Governance Committee
Kent Snyder
Director: Kent Snyder has served as a member of our board of directors since September 2004. Since September 2009, Mr. Snyder has been the Chief Executive Officer and Chairman of Senomyx, Inc. and from June 2003 was President and Chief Executive Officer and a director of Senomyx. In May 2008, Mr. Snyder assumed the role of Chairman of the board of directors of Senomyx. Previously, Mr. Snyder spent 10 years in various management positions with Agouron Pharmaceuticals, Inc., a Pfizer company, including President of Global Commercial Operations, Senior Vice President of Commercial Affairs and Vice President of Business Development. Mr. Snyder holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Rockhurst College.

Member of the Audit Committee
Member of the Compensation Committee
Matthew W. Strobeck
Director: Matthew W. Strobeck, Ph.D. has served as a member of our board of directors since April 2012. From June 2008 to October 2011, Dr. Strobeck was a partner, member of the management committee and member of the advisory board of Westfield Capital Management. Dr. Strobeck organized and led the purchase of Westfield in 2008 from Boston Private Bank, and prior to this transaction he was a member of the Westfield investment team. Dr. Strobeck currently serves as a member of the board of directors of Metabolix, Inc. Dr. Strobeck received a B.S. in biology from St. Lawrence University and a Ph.D. in cellular and molecular biology from the University of Cincinnati. In addition, Dr. Strobeck received an S.M. from the Harvard University-MIT Health Sciences Technology Program and an S.M. from the MIT Sloan School of Management.